Searched for
SPECIALTY DRUGS
MOFSL stays bullish on Sun Pharma; sees 16% upside on innovation pipelineSun Pharma's June quarter results met analyst expectations, signaling future growth. The company is expanding its specialty and innovative ...- The ethanol story is changing. Is investing in the ecosystem the better way? 15 stocks across different market cap segmentsThe ethanol story started simply enough: Cut India's dependence on imported crude oil. It would save foreign exchange. Give farmers a new a...
- Sun Pharma Q1 Results: Profit rises 27% YoY to Rs 2,895 crore; revenue climbs 10.5%Sun Pharma Q1 Results: Sun Pharma reported a 27% YoY rise in Q1 net profit to Rs 2,895 crore, while revenue grew 10% to Rs 15,300 crore, dr...
- These large- and mid-cap stocks can give more than 25% return in 1 year, according to analystsThe price of crude oil is down again despite the escalating tensions in the Gulf region. That augurs well for markets. This does not mean t...
- BDR Pharmaceuticals eyes controlling stake in Acme FormulationPAG acquired a controlling stake in Acme Formulation for $145 million (?1,054 crore) through its PAG Asia III buyout fund in 2021. Founder ...
- Tariff on generic drugs: Loud announcement, little consequence? 7 pharma stocks with upside potential of up to 31%The threat of a US tariff on Indian pharma is no longer a vague fear; or at least that is what President Trump wants us to believe. There i...
- Pharma mutual funds top return charts across horizons. Should investors chase the rally or stay cautious?Pharma mutual funds are leading returns in CY2026, driven by strong earnings, defensive demand, and US export growth. Despite recent outper...
- These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsAfter four days of relative outperformance, the Indian market is seemingly in trouble: Both the indices (the Nifty and Sensex) and market b...
- Hikal commissions cGMP pilot plant in Pune to strengthen pharmaceutical developmentHikal has commissioned an enhanced cGMP pilot plant at its Pune campus to strengthen its integrated capabilities for pharmaceutical develop...
- Risk is integral to the market; but there are different kinds of risk: 6 mid-cap stocks with upside potential of up to 21%We are in uncertain and volatile times. Does that mean investors should just sit out the downturn? While that is an option, the better opti...
- Glenmark gets USFDA nod for expanded use of RYALTRIS nasal sprayGlenmark Pharmaceuticals announced US FDA approval for RYALTRIS nasal spray. This approval expands its use to children aged six to twelve y...
- These large- and mid-cap stocks can give more than 25% return in 1 year, according to analystsOil is crucial for every part of the Indian economy: From government to consumer, its price impacts spending by every stakeholder. So, till...
- OneSource Specialty Pharma partners with Formycon AG to manufacture biosimilarsOneSource Specialty Pharma has announced a manufacturing partnership for biosimilars with Formycon AG. This collaboration will see OneSourc...
- Ethanol ecosystem: Judging fear by noise is not evidence; 15 stocks from the ecosystemSugar is one of the oldest distressed sectors in India. For decades it has swung between glut and shortage, carried heavy debt, was depende...
- For investors with an over 2-year perspective: 5 mid- and small-cap stocks with an upside potential of up to 26%This is a market to be selective in, not brave in. The safer way to play a turn in the market is to stay with businesses whose demand does ...
- India-UK FTA: Pharma industry flags regulatory priorities ahead of July 15 rolloutIndustry stakeholders expect stronger trade, investment, and research partnerships but say implementation clarity will determine the pact’s...
- These large- and mid-cap stocks can give more than 25% return in 1 year, according to analystsOver the next few trading sessions, the direction of indices like the Nifty and Sensex will be determined by news on ceasefire violations a...
- Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 25%As the market makes an attempt to move upward, there is a clear preference for sectors that are focused on the domestic market. Given this,...
- These large- and mid-cap stocks can give more than 20% return in 1 year, according to analystsIn just a few days, the Q1 earnings season for FY27 will start. But before that will come the season of business updates. And that needs to...
- For low risk-takers: 5 large-caps from different sectors with an upside potential of up to 31%Now, there is nothing wrong with being bullish, because it has always paid to be bullish. Yes, one might argue that it has not paid in the ...
Load More
